Celldex stops Phase Ib/II trial in melanoma due to GI toxicities after enrolling three patients
The study had enrolled three out of its 10-patient target when it was stopped, a source said.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more